{
    "clinical_study": {
        "@rank": "148047", 
        "acronym": "AIN", 
        "arm_group": {
            "arm_group_label": "RFA", 
            "arm_group_type": "Experimental", 
            "description": "Assess the feasibility, safety, and efficacy of RF to the anal canal using the HALO Ablation System to eradicate anal HSIL lesions"
        }, 
        "brief_summary": {
            "textblock": "This is a Single-center prospective pilot trial involving up to 22 subjects. This study will\n      assess the feasibility, safety, and efficacy of radiofrequency ablation (RFA) to the anal\n      canal using the FDA cleared HALO Ablation System to eradicate anal HSIL lesions in\n      HIV-negative subjects with intra-anal intraepithelial neoplasia (AIN). The study\n      intervention will demonstrate that a reasonable proportion of subjects will be\n      histologically cleared of their anal HSIL within the ETZ in a tolerable and relatively safe\n      manner"
        }, 
        "brief_title": "A Trial of Radiofrequency Ablation for Anal Intraepithelial Neopplasia Using the HALO Ablation System", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV-negative Subjects With Intra-anal Intraepithelial Neoplasia Containing High-grade Squamous Intraepithelial Lesions.", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Uterine Cervical Dysplasia", 
                "Carcinoma in Situ"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-75 years\n\n          -  HRA 2 to 12 weeks prior to the 0 month RFA visit yielding one or more flat,\n             non-condylomatous biopsy-proven HSILs that are\n\n               1. Located entirely within in the eligible treatment zone\n\n               2. Contiguous with the squamocolumnar junction Eligible treatment zone (ETZ) is\n                  defined as\n\n               1. 3 cm above the dentate line to the anocutaneous line\n\n               2. Half of the anorectal circumference (meaning no more than two contiguous\n                  quadrants)\n\n          -  If female of child-bearing age, negative pregnancy test within 8 weeks of the 0 month\n             RFA visit and declared intent to remain on birth control throughout the trial, or,\n             declaration of infertility defined as subject report of status as post-menopausal or\n             surgically sterile (status post hysterectomy or tubal ligation).\n\n          -  HIV negative, ELISA/Western blot test obtained within 12 weeks of the 0 month RFA\n             visit\n\n        Exclusion Criteria:\n\n          1. Any biopsy-proven HSIL entirely outside of the ETZ\n\n          2. Any biopsy-proven HSIL partially within the ETZ (for example, an HSIL lesion with\n             extension to the perianal skin)\n\n          3. Any condylomas in the eligible treatment zone > 1/2 cm diameter\n\n             \u2022 Note: Condylomas in the eligible treatment zone < 1/2 cm in diameter must be\n             excised or cauterized (not treated topically or with IRC) before or during Visit 1 (0\n             month RFA visit)\n\n          4. Any anal or rectal pathology requiring treatment including ulcer, fistula, fissure,\n             stenosis or proctitis\n\n          5. History of or present anal or rectal cancer\n\n          6. History of pelvic radiation therapy\n\n          7. History of HPV vaccination or plans to initiate HPV vaccination during the trial\n\n          8. History of ablation or resection therapy within the ETZ other than cauterization or\n             excision of condyloma(s)\n\n          9. History of topical therapy (Imiquimod, 5-FU) within 6 months prior to the 0 month RFA\n             visit within the ETZ\n\n         10. Hemorrhoids > grade II\n\n         11. Fecal incontinence (that the investigator feels may impair healing)\n\n         12. Concurrent disease requiring systemic immunosuppression therapy\n\n         13. Concurrent malignancy requiring systemic therapy\n\n         14. Life expectancy < 2 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "22", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970787", 
            "org_study_id": "B-250"
        }, 
        "intervention": {
            "arm_group_label": "RFA", 
            "intervention_name": "Radiofrequency Ablation (RFA) using the HALO Ablation System", 
            "intervention_type": "Device", 
            "other_name": "Barrx Ablation System"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 25, 2013", 
        "location": {
            "contact": {
                "email": "mkhan@lasersurgerycare.com", 
                "last_name": "Murad Khan", 
                "phone": "212-242-6500"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10011"
                }, 
                "name": "Laser Surgery Center"
            }, 
            "investigator": {
                "last_name": "Stephen Goldstone, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Trial of Radiofrequency Ablation for Anal Intraepithelial Neopplasia Using the HALO Ablation System", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Histologic clearance of HSIL within the ETZ on a subject basis at 12 months from first RFA", 
            "measure": "Clearance of HSIL", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970787"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Technical feasibility of applying RFA to the anal canal. Physician's assessment of ablation as optimal (complete ablation) versus sub-optimal (incomplete ablation)in the affected area in the anal canal.", 
                "measure": "Feasibility and ease of technique", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Subject tolerability of the RFA procedure as measured by severity. Mild:  Awareness of signs and symptoms, but easily tolerated; are of a minor irritant type; causing no loss of time from normal activities; symptoms would not require medication or a medical intervention; asymptomatic lab findings; marginal clinical relevance; signs and symptoms are transient.\nModerate: Discomfort severe enough to cause interference with usual activities; minimal intervention.\nSevere: Incapacitating with inability to do work or usual activities; signs and symptoms may be of systemic nature or require medical evaluation or treatment.", 
                "measure": "Tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Any related adverse event occuring in patients enrolled in this study. Event type and relationship to the device or procedure will be measured.", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Histologic progression of HSIL to cancer as measured in biopsies read at the central pathology lab.", 
                "measure": "Progression of HSIL to cancer", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Covidien, GI Solutions", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Covidien, GI Solutions", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}